Seminal Vesicle Invasion
Seminal vesicle invasion describes prostate cancer that has grown beyond the prostate itself into one or both seminal vesicles—the paired glands sitting just behind and above the prostate that produce most of the fluid in semen. It is a specific staging finding rather than a separate disease, and it matters because it changes the stage to T3b, indicates more aggressive behaviour, and directly influences which treatments are recommended. It is identified primarily on multiparametric MRI before treatment, and confirmed on pathology when surgery is performed. Its presence does not mean cancer has spread beyond the pelvis, and many men with this finding are still treated with curative intent, though usually with more intensive therapy than localised disease requires.
What is it?
The seminal vesicles are a pair of coiled, sac-like glands roughly five centimetres long, sitting behind the bladder and immediately above and behind the prostate. They produce the majority of seminal fluid—a thick, fructose-rich secretion that nourishes sperm—which drains through the ejaculatory ducts, passing through the prostate to join the urethra.
Their position and their duct connection to the prostate are what make them relevant in prostate cancer. They sit directly against the base of the prostate, and the ejaculatory ducts provide a physical pathway running from the vesicles into the gland.
Seminal vesicle invasion means prostate cancer has grown into the muscular wall of one or both vesicles. It is a staging descriptor rather than a distinct disease, and in the TNM staging system it defines stage T3b. This sits above T3a, which describes cancer extending through the prostate capsule into surrounding tissue without reaching the vesicles, and below T4, which describes invasion of adjacent structures such as the bladder neck, rectum, or pelvic wall.
Cancer reaches the seminal vesicles by several routes. The most common is direct extension along the ejaculatory ducts, with tumour growing up the duct from within the prostate. It can also spread directly through the base of the prostate into the adjacent vesicle, or spread through surrounding tissue and invade the vesicle from outside. Isolated deposits within a vesicle without continuity from the prostate are uncommon.
Because most invasion travels through the base of the gland or along the ducts, tumours arising near the prostate base carry higher risk than those in the apex.
The finding matters for several concrete reasons.
It reclassifies the disease as locally advanced. Prostate cancer confined to the gland is treated with the expectation that surgery or radiotherapy alone may be sufficient. Once cancer has reached the seminal vesicles, the likelihood of microscopic disease having spread further is meaningfully higher, and treatment is intensified accordingly.
It is an independent predictor of outcome. Seminal vesicle invasion is associated with higher rates of PSA recurrence after treatment, a greater likelihood of lymph node involvement, and a higher risk of distant spread. It correlates strongly with other adverse features—higher Grade Group, higher PSA, greater tumour volume—and is one of the features that places a man in the high-risk category regardless of his other results.
It changes treatment planning directly. Radiotherapy fields are extended to include the seminal vesicles and often the pelvic lymph nodes. The duration of hormonal therapy given alongside radiotherapy is longer. If surgery is performed, the likelihood of needing additional treatment afterwards is substantially higher, and this is discussed in advance rather than as a surprise.
It is worth being clear about what the finding does not mean. It does not mean the cancer has spread to bones or distant organs; those are separate questions answered by staging scans. It does not mean cure is impossible—many men with T3b disease are treated with curative intent and remain free of recurrence long term. And it does not, on its own, dictate a single treatment path; the choice between surgery-based and radiotherapy-based approaches remains open in most cases.
Symptoms are generally absent. The invasion itself does not usually produce anything a man would notice, and the finding almost always emerges from imaging or from pathology after surgery rather than from a complaint.
Where symptoms exist, they typically reflect the prostate cancer or coexisting benign enlargement: urinary hesitancy, weak stream, frequency, urgency, and incomplete emptying. Blood in the semen can occur with seminal vesicle involvement, though it is far more often caused by benign conditions including infection, inflammation, recent instrumentation, or minor vessel rupture, and in younger men it is almost always benign. Reduced ejaculate volume, painful ejaculation, and new erectile difficulty are occasionally described.
Diagnosis rests primarily on MRI.
Multiparametric MRI of the prostate is the main tool for identifying seminal vesicle invasion before treatment. Normal seminal vesicles have a characteristic appearance—thin-walled, fluid-filled, grape-like structures that appear bright on T2-weighted images. Invasion produces several recognised signs: loss of that normal bright signal, replaced by lower-signal tumour tissue; direct extension of tumour visible along the ejaculatory duct; thickening or irregularity of the vesicle wall; abnormal restricted diffusion and enhancement matching the primary tumour; and obliteration of the normal angle between the prostate and the vesicle.
An important characteristic of MRI here is that its specificity is high while its sensitivity is more modest. In practical terms, when MRI reports seminal vesicle invasion it is usually correct, but a normal-appearing seminal vesicle does not exclude microscopic invasion that only pathology will reveal. This asymmetry explains why some men have surgery for apparently organ-confined disease and are found afterwards to have T3b disease on the specimen.
Several conditions can mimic invasion on imaging and account for occasional false positives, including haemorrhage after biopsy, inflammation, amyloid deposition in the vesicle walls—which is common with age and can lower signal—and post-treatment changes. Timing MRI at least several weeks after biopsy reduces the confounding effect of post-biopsy haemorrhage.
PSMA PET-CT is used for overall staging in high-risk disease, principally to detect lymph node and distant involvement rather than to assess local extension, where MRI has better spatial resolution.
Transrectal ultrasound-guided biopsy of the seminal vesicles is performed occasionally, when confirming or excluding involvement would genuinely change the treatment plan.
Definitive confirmation comes from pathological examination of the surgical specimen after radical prostatectomy, where the pathologist assesses whether tumour has invaded the muscular wall of the vesicle. Involvement of only the surrounding connective tissue, or of the portion of the vesicle within the prostate, is classified differently, and this distinction is made carefully because it affects staging.
Important to Know
Seminal vesicle invasion places a man in the high-risk or locally advanced category, which changes the intensity of treatment rather than removing the possibility of cure. Care is coordinated by a multidisciplinary team including urology, radiation oncology, medical oncology, radiology, and pathology, and this is a situation where multidisciplinary input genuinely matters, since more than one reasonable approach exists.
Active surveillance is not appropriate for disease with seminal vesicle invasion. This is one of the clearer boundaries in prostate cancer management, and men who have read about surveillance for low-risk disease should understand that it does not apply here.
Radiotherapy combined with androgen deprivation therapy is a standard approach and is well supported by trial evidence in high-risk disease. Radiation fields typically include the prostate, the seminal vesicles, and frequently the pelvic lymph nodes. Hormonal therapy is given for an extended period—commonly between eighteen months and three years—because trials have consistently shown that longer courses improve outcomes in high-risk disease compared with short courses or radiotherapy alone. Modern techniques including image-guided and intensity-modulated radiotherapy, and in some centres rectal spacer placement, reduce side effects compared with older approaches.
Radical prostatectomy with extended pelvic lymph node dissection is a reasonable alternative, and the seminal vesicles are removed as part of the standard operation regardless of whether invasion is suspected. Men should understand in advance that when seminal vesicle invasion is confirmed on the specimen, the likelihood of requiring radiotherapy afterwards is high. Contemporary practice has moved toward early salvage radiotherapy—treating when PSA begins to rise after surgery—rather than adjuvant radiotherapy given to everyone, since trial evidence showed comparable outcomes while sparing radiotherapy in men who would not have recurred. Adjuvant treatment is still considered in selected cases with multiple adverse features.
Treatment intensification is an evolving area. For very high-risk disease, adding further systemic agents to hormonal therapy has improved outcomes in trials, and eligibility depends on specific disease features. This is a rapidly changing field, and it is reasonable to ask whether current trial evidence or open studies apply to a particular situation.
Nerve-sparing surgery is generally limited on the side of documented invasion, since preserving the nerve bundles adjacent to involved tissue risks leaving cancer behind. This has implications for erectile function that should be discussed before surgery rather than afterwards.
Outcomes vary considerably and are worth framing accurately. Seminal vesicle invasion carries a higher risk of recurrence than organ-confined disease, and PSA recurrence occurs in a substantial proportion of men. However, PSA recurrence is not the same as metastatic disease or death from prostate cancer, and many men with recurrence are successfully treated with further therapy and live for many years. Unilateral invasion carries a better outlook than bilateral. Outcome depends heavily on Grade Group, PSA level, lymph node status, surgical margins, and how the disease responds to treatment, so a single staging finding does not determine an individual’s prognosis.
Follow-up after treatment is with regular PSA testing, which is sensitive to recurrence. A rising PSA prompts further imaging, where PSMA PET-CT is considerably better than conventional scans at locating recurrence at low PSA levels, and this can allow targeted salvage treatment.
Side effects of treatment deserve attention alongside cancer control. Extended androgen deprivation therapy causes hot flushes, fatigue, loss of muscle mass, weight gain, bone density loss, mood changes, and loss of libido and erectile function. Bone protection, exercise, and cardiovascular and metabolic monitoring are important parts of care during prolonged hormonal treatment. Surgery carries risks of urinary incontinence and erectile dysfunction, and radiotherapy carries bowel and urinary irritative effects. These are legitimate considerations in choosing between approaches, not afterthoughts.
Genetic testing is increasingly recommended in high-risk and locally advanced disease. Identifying BRCA2 or other mutations affects treatment options, including eligibility for specific targeted therapies, and has implications for relatives who may benefit from their own assessment.
Care is coordinated by a multidisciplinary team, and a second opinion is entirely reasonable in this setting given that treatment approaches differ meaningfully and the decision has long-term consequences. Imaging, pathology, PSA, and clinical findings are interpreted together alongside age, general health, and personal priorities rather than in isolation.
Patient education plays an important role. Understanding that seminal vesicle invasion is a local staging finding rather than evidence of distant spread, that cure remains achievable, why treatment is more intensive than for confined disease, why hormonal therapy is given for years rather than months, and that PSA recurrence is treatable rather than final all contribute to appropriate care and informed decision-making.
Red flag symptoms include inability to pass urine, which is a urological emergency; blood in the urine, particularly with clots; persistent bone pain in the back, hips, ribs, or pelvis; unexplained weight loss; new leg swelling; and new leg weakness, numbness, difficulty walking, or new bladder or bowel incontinence, which may indicate spinal cord compression and requires immediate assessment. A rapidly rising PSA after treatment also warrants prompt review.